Success Story: From Medication Safety Research to NIW Approval for a Clinical Pharmacology Expert
Client’s Testimonial:
"I truly appreciate your support throughout my I-140 NIW petition process, and I am very pleased with the approval.”
On June 20th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Sr. Clinical Research Manager in the Field of Clinical Pharmacology (Approval Notice).
General Field: Clinical Pharmacology
Position at the Time of Case Filing: Sr. Clinical Research Manager
Country of Origin: South Korea
State of Residence at the Time of Filing: South Korea
Approval Notice Date: June 20th, 2026
Processing Time: 7 months, 28 days (Premium Processing Upgrade Requested)
Case Summary:
Unsafe medication use remains a significant public health challenge, particularly for vulnerable populations that are often underrepresented in clinical trials. Generating reliable real-world evidence is increasingly important for helping healthcare professionals, policymakers, and regulators make informed decisions about medication safety. It was within this context that we helped a clinical pharmacology expert secure approval of an I-140 National Interest Waiver (NIW) petition.
The client, who holds a Ph.D. in Pharmacy, focuses on using pharmacy claims data, national health databases, and patient-reported outcomes to evaluate medication safety and improve public health outcomes. At the time of filing, the client's proposed endeavor centered on generating real-world evidence regarding medication safety, particularly among vulnerable populations such as pregnant women. We demonstrated that this work addresses critical evidence gaps that affect patient safety, healthcare decision-making, and broader public health priorities in the United States.
To establish the client's qualifications and ability to advance this endeavor, we presented evidence of a sustained record of scholarly achievement and practical expertise in clinical pharmacology, pharmacoepidemiology, and drug safety research. The case highlighted several indicators of professional accomplishment:
- 10 peer-reviewed journal articles, including 7 first-authored publications
- 2 research abstracts, including 1 first-authored abstract
- 479 citations to published research
These metrics were important not simply because of their quantity, but because they demonstrated that other researchers had repeatedly relied upon the client's findings. From an adjudicative perspective, citations serve as evidence that a researcher's work has informed subsequent scientific investigations. In the client's case, nearly 500 citations indicated sustained engagement from the research community and independent validation of the significance of the underlying work. We also emphasized that some of the client's publications achieved citation performance that exceeded field averages for their publication years, providing additional evidence of influence beyond raw citation counts alone.
The petition further demonstrated how the client's research had addressed important questions related to medication safety, pregnancy outcomes, drug risk evaluation, and public health. We showed that the client's work contributed practical evidence that can help improve prescribing practices, support safer medication use, and reduce preventable adverse drug events. Because these issues affect healthcare systems, patients, and public health initiatives on a broad scale, we argued that the proposed endeavor possessed both substantial merit and national importance under the NIW framework.
Rather than focusing solely on past accomplishments, we also documented the client's future plans to continue conducting research using real-world healthcare data sources to generate evidence on medication safety and health outcomes. We demonstrated that the client was well-positioned to advance this work based on a combination of advanced education, specialized expertise, prior research success, and a documented record of scholarly contributions.
As a result of the strong evidence presented regarding the importance of the proposed endeavor and the client's ability to advance it, the I-140 NIW petition was approved. We are pleased to have assisted this clinical pharmacology expert in obtaining this favorable outcome and look forward to the continued impact of the client's research on medication safety, patient care, and public health.